NCT04533919 2026-04-06
Validation of Pre-clinical Nano-Based Analgesics in Cells From Human Dorsal Root Ganglia
M.D. Anderson Cancer Center
Withdrawn
Clinical Trials
25 trialsNCT04482933 2026-02-10
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
Phase 2 Withdrawn
NCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT06163664 2026-01-13
Role of ChatGPT in Vestibular Schwannoma Management
University of Southern California
Phase NA Withdrawn
NCT06466798 2026-01-08
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
The University of Texas Health Science Center, Houston
Phase 1 Withdrawn
NCT03261726 2025-12-19
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Henry Ford Health System
Phase NA Withdrawn
NCT05669326 2025-12-03
NODDI-TRACT
GCS Ramsay Santé pour l'Enseignement et la Recherche
Phase NA Withdrawn
NCT06776406 2025-11-25
Head Stabilization in Whole Brain RT
Abramson Cancer Center at Penn Medicine
Phase NA Withdrawn
NCT05904704 2025-11-14
Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors
OHSU Knight Cancer Institute
Phase NA Withdrawn
NCT05341947 2025-10-22
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Withdrawn
NCT05720624 2025-10-22
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Mayo Clinic
Phase 1 Withdrawn
NCT03974204 2025-09-26
Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.
Centre Oscar Lambret
Phase NA Withdrawn
NCT04500548 2025-09-10
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05789862 2025-08-29
Behavioral Health Evaluation and Intervention Program for Patients Undergoing Craniotomy
University of California, San Francisco
Phase NA Withdrawn
NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06501911 2025-07-22
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
University of Nebraska
Phase 1 Withdrawn
NCT04838782 2025-07-08
Role of Repeat Resection in Recurrent Glioblastoma
University of Alberta
Phase NA Withdrawn
NCT07046481 2025-07-01
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
Region Skane
Phase NA Withdrawn
NCT05620914 2025-06-15
PARAMETer
Duke University
Phase 2 Withdrawn
NCT06494046 2025-06-04
Defining Musical Toxicity and Its Effect on Patient Well-being
Mayo Clinic
Withdrawn
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT05927610 2025-05-21
Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Withdrawn
NCT02145910 2025-05-02
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Thomas Jefferson University
Phase 1 Withdrawn
NCT04667715 2025-05-02
BBBD
InSightec
Phase NA Withdrawn